ArticleThe EMBO journal1996
The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
Article in The EMBO journal, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 75 citations in OpenAlex.
- MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.BMC cancer · 2018Trial
- NF-κB c-Rel Dictates the Inflammatory Threshold by Acting as a Transcriptional Repressor.iScience · 2020Article
- Constitutive activation and overexpression of NF-κB/c-Rel in conjunction with p50 contribute to aggressive tongue tumorigenesis.Oncotarget · 2018Article
- The Direct and Indirect Roles of NF-κB in Cancer: Lessons from Oncogenic Fusion Proteins and Knock-in Mice.Biomedicines · 2018Review
- Downregulation of RelA (p65) by Rapamycin Inhibits Murine Adipocyte Differentiation and Reduces Fat Mass of C57BL/6J Mice despite High Fat Diet.ISRN obesity · 2014Article
- CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.Journal of virology · 2008Article
- Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma.World journal of gastroenterology · 2008Article
- RelB-dependent stromal cells promote T-cell leukemogenesis.PloS one · 2008Article
- Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration.Pharmacology & therapeutics · 2007Review
- Article
- Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models.Oncogene · 2006Review
- Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses.Oncogene · 2006Review
- Article
- PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia.Oncogene · 2005Article
- Nuclear factor-kappaB: its role in health and disease.Journal of molecular medicine (Berlin, Germany) · 2004Review
- Review
- Article
- Article
- Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.Journal of virology · 2002Article
- New insights into the role of nuclear factor-kappaB in cell growth regulation.The American journal of pathology · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oncogene product from the avian reticuloendotheliosis virus strain T, v-Rel, is a member of the Rel/ NF-kappa B family of transcription factors. The mechanism by which v-Rel induces oncogenic transformation remains unclear. Several attempts to transform mammalian cells with v-Rel have failed, suggesting that v-Rel transformation may be a species-specific event. However, here we demonstrate that v-Rel, but not a truncated c-Rel, expressed under the control of the lck promoter, efficiently induced malignancies in transgenic mice. Most of the animals died before 10 months of age and developed immature, multicentric aggressive T-cell leukemia/lymphomas. Most tumors contain CD4+CD8+ cells or CD4-CD8+ cells, which have an immature rather than a mature peripheral phenotype. No tumor development was observed in control littermates and transgenic mice expressing a truncated form of c-Rel. Tumor formation was correlated with the presence of constitutive p50/v-Rel DNA binding activity and overexpression of several kappa B-regulated genes in v-rel transgenic thymocytes. However, v-Rel is also transforming in transgenic thymocytes lacking p50, indicating that p50/v-Rel heterodimer formation is not essential for the transforming activity of v-Rel. The transforming activity of v-Rel in p50 null mice has been identified as v-Rel/v-Rel homodimers. Since tumors represent immature T-lymphocytes, constitutive v-Rel expression appears to be leukemogenic at earlier stages of T-cell development. These v-Rel mice should aid in the study of lymphoma development, T-cell development and NF-kappa B regulation.
Indexed as
Identifiers
8670867PMC451988W1846940228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.